Ventana Medical Systems, Inc.

Genentech, Inc.

National Cancer Center

Nihon University School of Medicine

Hiro Nitta

Michael S Barnes

Thomas M Grogan

Esteban Roberts

Crystal Schemp

Christopher Bieniarz

Atsushi Ochiai

Shalini Singh

Penny Towne

June F Clements

Brian Daniel Kelly

Wenjun Zhang

Adrian E Murillo

Shinobu Masuda

Nelson Alexander

Stacey Stanislaw

Fabien Gaire

Alisa Tubbs

Bharathi Vennapusa

Mike Farrell

Tom Grogan

Masafumi Kurosumi

Mary T Padilla

Michael Barnes

Donald G Munroe

Takeshi Kuwata

Akio Kaito

Eslie Dennis

Leigh A Henricksen

Sasagu Kurozumi

James Ranger-Moore

Edmundo David Del Valle

Amy A Lo

Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IHC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.

Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (ALK) as a marker

Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IBC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.

The present disclosure relates to systems and methods for analyzing chromosomal translocations, and in particular to analysis of chromosomal translocation by in situ hybridization.

Method of analyzing chromosomal inversions

Embodiments of substrates and processes for chromogenic detection, and in particular pyrazolyl dihydrogen phosphate compounds, are disclosed.

Substrates for chromogenic detection and methods of use in detection assays and kits

Growing community of inventors

Tucson, AZ, United States of America

Hiro Nitta